ReNeuron launches first stem cell trial for stroke

In yet another new 'first' for stem cell companies, ReNeuron says that it dosed the first patient in a small stroke study, with an elderly patient on the receiving end of a series of stem cell injections in the brain. It's the first such clinical trial in the world. "In this trial, we are seeking to establish the safety and feasibility of stem cell implantation, which will require careful follow-up of the patients who take part," said Professor Keith Muir. Investigators plan to treat a dozen people with ReNeuron's neural stem cells, which are extracted from fetuses. Story

Suggested Articles

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells.